A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Public ClinicalTrials.gov record NCT03783403. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.
Study identification
- NCT ID
- NCT03783403
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 206 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 1, 2019 (Actual)
- Primary completion
- Aug 5, 2024 (Actual)
- Completion
- Aug 5, 2024 (Actual)
- Last update posted
- Sep 19, 2024
2019 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 105 | Birmingham | Alabama | 35294 | — |
| Local Institution - 101 | Scottsdale | Arizona | 85258 | — |
| Local Institution - 112 | Sacramento | California | 95817 | — |
| Rocky Mountain Cancer Centers, LLP [Aurora-COAU] | Aurora | Colorado | 80012 | — |
| Local Institution - 115 | St Louis | Missouri | 63110 | — |
| Local Institution - 110 | New York | New York | 10016 | — |
| Local Institution - 109 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 106 | Oklahoma City | Oklahoma | 73104 | — |
| Local Institution - 113 | Portland | Oregon | 97213 | — |
| Local Institution - 107 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 102 | Nashville | Tennessee | 37203-1625 | — |
| Local Institution - 108 | Houston | Texas | 77030 | — |
| Local Institution - 103 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03783403, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 19, 2024 · Synced Oct 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03783403 live on ClinicalTrials.gov.